Active Biotech
- Tel: +46 46 19 20 00
- Contact this Company »
- Visit Web Site »
The Active Biotech of today originated from a research project at Pharmacia now known as the TTS project. In 1991, Pharmacia set up a new research facility in Lund to focus on this work. When Pharmacia merged with Upjohn in 1997, the Lund department was threatened with closure.
This was when Active Biotech bought both the facility and the operations, including the 165 or so researchers. The research portfolio included both the TTS and the SAIK projects.
Our portfolio includes innovative substances that modulate the human immune system. We have made most progress in developing products designed to treat multiple sclerosis, as well as lung, renal and pancreatic cancer.
In order to spread our risks and costs, and to optimise both time to market and market efficiency, we need collaboration partners. These are primarily major pharmaceutical and biotech companies.
Active Biotech focuses on developing pharmaceuticals for medical fields in which the immune system plays a central role. Our pharmaceutical development is based on our specialist know-how in the field of immunology.
We possess a unique infrastructure that includes highly experienced researchers who combine cutting edge expertise with efficient project work focusing on clearly defined targets.
Contact Us
Active Biotech AB
Box 724
SE-220 07 Lund
Sweden
Tel: +46 46 19 20 00
Fax: +46 46 19 20 50
